Economic implications of inadequate treatment of venous thromboembolism and potential solutions

Journal of Pharmacy Practice

Volumn 27, Issue 2, 2014, Pages 178-186

  Dobesh, Paul P ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

Author keywords

anticoagulants; direct thrombin inhibitor; direct Xa inhibitor; pharmacoeconomics; venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; CANCER RISK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE EXACERBATION; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MORBIDITY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; ECONOMICS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84898983883     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013513802     Document Type: Article

References (56)

1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003 ; 107 (suppl 1). I4 - I8
2. Fanikos J, Piazza G, Zayaruzny M, et al. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009 ; 102 (2). 688-693
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2008 ; 133 (6 suppl). 381S - 453S
4. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 ; 153 (1). 8-18
5. Spyropoulos AC. Risk assessment of venous thromboembolism in hospitalized medical patients. Curr Opin Pulm Med. 2010 ; 16 (5). 419-425
6. Stashenko GJ, Tapson VF. Prevention of venous thromboembolism in medical patients and outpatients. Nat Rev Cardiol. 2009 ; 6 (5). 356-363
7. Agency for Healthcare Research and Quality. VTE: Preventing Hospital-Acquired Venous Thromboembolism. www.ahrq.gov/qual/vtguide/vtguideapa. htm. Accessed January 29, 2013.
8. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007 ; 13 (6). 475-486
9. Knight KK, Wong J, Hauch O, et al. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients. Value Health. 2005 ; 8 (3). 191-200
10. Huse DM, Cummins G, Taylor DC, et al. Outpatient treatment of venous thromboembolism with low-molecular- weight heparin: an economic evaluation. Am J Manag Care. 2002 ; 8 (1 suppl). S10 - S16
11. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004 ; 164 (15). 1653-1661
12. O'Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics. 2002 ; 20 (9). 603-615
13. MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health-Syst Pharm. 2006 ; 63 (20 suppl 6). S5 - S15
14. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (2 suppl). e419S - e494S
15. Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American college of physicians and the American academy of family physicians. Ann Intern Med. 2007 ; 146 (3). 204-210
16. Caprini JA, Tapson VF, Hyers TM, et al. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg. 2005 ; 42 (4). 726-733
17. Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007 ; 167 (14). 1471-1475
18. Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001 ; 1 (1). 7-26
19. Goldhaber SZ, Tapson VF. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004 ; 93 (2). 259-262
20. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy. 2009 ; 29 (8). 943-953
21. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003 ; 107 (suppl 1). I9 - I16
22. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997 ; 82 (4). 423-428
23. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000 ; 160 (6). 761-768
24. Haines ST. Venous thromboembolism: pathophysiology and clinical presentation. Am J Health Syst Pharm. 2003 ; 60 (suppl 7). S3 - S5
25. Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev. 2002 ; 16 (3). 155-165
26. Kahn SR, Elman EA, Bornais C, et al. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. Thromb Haemost. 2005 ; 93 (3). 499-502
27. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009 ; 33 (2). 325-331
28. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 ; 350 (22). 2257-2264
29. Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm. 2005 ; 11 (8). 663-673
30. Ollendorf DA, Vera-Llonch M, Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm. 2002 ; 59 (18). 1750-1754
31. Caprini JA, Botteman MF, Stephens JM, et al. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health. 2003 ; 6 (1). 59-74
32. Bergqvist D, Jendteg S, Johansen L, et al. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med. 1997 ; 126 (6). 454-457
33. Kirson NY, Birnbaum HG, Ivanova JI, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): direct cost of illness in the US privately insured population. Chest. 2010 ; 138 (4 suppl). 375A
34. Hoffman C, Rice D, Sung HY. Persons with chronic conditions: their prevalence and costs. JAMA. 1996 ; 276 (18). 1473-1479
35. Bergan JJ, Schmid-Schonbein GW, Smith PD, et al. Chronic venous disease. N Engl J Med. 2006 ; 355 (5). 488-498
36. Wilke T, Muller S. Nonadherence in outpatient thromboprophylaxis after major orthopedic surgery: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2010 ; 10 (6). 691-700
37. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 ; 133 (6 suppl). 340S - 380S
38. Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Postgrad Med J. 2008 ; 84 (991). 252-258
39. Verhovsek M, Motlagh B, Crowther MA, et al. Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. BMC Geriatr. 2008 ; 8: 13
40. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 ; 133 (6 suppl). 160S - 198S
41. Kakkar AK, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg. 2010 ; 251 (2). 330-338
42. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 ; 361 (24). 2342-2352
43. Schulman S, Kakkar AK, Schellong SM. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Blood. 2011 ; 118 (21). 205
44. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 ; 363 (26). 2499-2510
45. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 ; 366 (14). 1282-1291
46. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008 ; 47 (5). 285-295
47. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single dose BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005 ; 78 (4). 412-421
48. van Bellen B, Prins M, Bamber L, et al. Reduction of initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Blood. 2012 ; 120 ( 21 ):
49. Seaman CD, Ragni MV, Smith KJ. Cost effectiveness of rivaroxaban versus warfarin for the prevention of recurrent venous thromboembolism. Blood. 2012 ; 120 ( 21 ):
50. Prins M, Bamber L, Cano S, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism. Blood. 2012 ; 120 ( 21 ):
51. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009 ; 48 (1). 1-22
52. Agnelli G, Buller HR, Cohen A, et al. for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 ; 369 (9). 799-808
53. Agnelli G, Buller HR, Cohen A, et al. for the AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 ; 368 (8). 699-708
54. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 ; 369 (15). 1406-1415
55. Hillarp A, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011 ; 9 (1). 133-139
56. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012 ; 87 (suppl 1). S141 - S145